Atrium Health, formerly Carolinas HealthCare System, is a hospital network with more than 70,000 employees. It operates 40 hospitals, six freestanding emergency departments, over 30 urgent care centers, and more than 1,400 care locations in the American states of North Carolina, South Carolina, Georgia, and Alabama. It provides care under the Atrium Health Wake Forest Baptist name in the Winston-Salem, North Carolina, region, Atrium Health Navicent in the Macon, Georgia area, and Atrium Health Floyd in the Rome, Georgia area. Atrium Health offers pediatric, cancer, and heart care, as well as organ transplants, burn treatments and specialized musculoskeletal programs.Legally, Atrium Health is The Charlotte-Mecklenburg Hospital Authority, a municipal hospital authority established under North Carolina's Hospital Authorities Act (North Carolina General Statutes chapter 131E, part 2). The authority is governed by a self-perpetuating board of commissioners which nominates new commissioners to fill its own vacancies; the chair of the Mecklenburg Board of County Commissioners can approve or veto those nominations but not make nominations of her own.
Limb-girdle muscular dystrophy R2-dysferlin related (LGMD-R2) is a progressive muscle condition with marked variability in disease course, making prognosis challenging. Quantitative MRI (qMRI) has emerged as a complementary tool that may detect progression earlier and more precisely. Integrating different data modalities is challenging with conventional approaches, and artificial intelligence (AI) can help overcome this. Our aim is to develop robust models capable of predicting clinical progression in LGMD-R2 by incorporating AI-based techniques into the analysis pipeline. Data from 188 COS 1 participants were analysed. Disease progression was assessed using the North Star Assessment for Limb Girdle type Muscular Dystrophies (NSAD). Ambulatory individuals with a maximum NSAD ≥ 20 were included, and progression trajectories were identified through hierarchical clustering. Feature selection was performed using a machine learning pipeline, and top predictors were entered into stepwise logistic regression to build clinical-only and combined clinical-MRI models. Two stages of progression were identified, a fast one with a mean three-year loss of 14.4 NSAD points, and a moderate one, with a mean loss of 3.8 NSAD points. The combined model achieved better balanced accuracy than the clinical-only one (83.7
INTRODUCTION:Each year, millions of people experience recurrent diverticulitis episodes. Elective sigmoid colon resection reduces the risk of recurrence, but The American Society of Colon and Rectal Surgeons recommends individualising surgical decisions based on the impact of the condition on a patient's quality of life (QoL). However, no threshold for QoL impairment has been established to guide decision-making, and evidence comparing elective colectomy with medical management in terms of QoL limitation is limited. To address these gaps and to guide treatment decision-making, we designed the Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) trial.The COSMID trial is a large, pragmatic randomised trial including patients with QoL-limiting diverticulitis that aims to determine if partial colectomy is superior to medical management and explore subgroups that are more likely to respond to each treatment. METHODS AND ANALYSIS:COSMID will recruit 250 English-speaking and Spanish-speaking adults with imaging-confirmed and QoL-limiting diverticulitis (defined using a modified diverticulitis-related QoL survey). Participants are randomly assigned to undergo elective partial colectomy or receive comprehensive medical management (eg, selected from options including fibre, probiotics, mesalamine and rifaximin). A total of 100 patients who decline randomisation but consent to follow-up will be included in a parallel observational cohort. The primary outcome is the time-averaged score of the Gastrointestinal Quality of Life Index at 6, 9 and 12 months after randomisation. Secondary outcomes include clinical adverse events, healthcare utilisation, recurrent episodes of diverticulitis and additional patient-reported outcomes like the Diverticulitis Quality of Life instrument, decisional regret and work productivity. Exploratory analyses aim to identify differential treatment effects based on patients' characteristics. ETHICS AND DISSEMINATION:This trial was approved by the Vanderbilt Institutional Review Board (IRB) on 26 August 2019 (IRB #191217). Vanderbilt serves as the institutional review board of record for the following study sites: Albany Medical College, Allegheny Health, Atrium Health Carolinas Medical Center, Virginia Mason Medical Center, Boston University Medical Center, Cedars-Sinai Medical Center, UT Health Lyndon B. Johnson Hospital, Medical University of South Carolina, New York-Presbyterian Queens, Stanford University, University of Pennsylvania, University of California San Diego, University of California San Francisco, University of Colorado Denver, University of Florida, University of Iowa, University of Utah, University of Washington Medical Center, University of South Florida, University of Rochester Medical Center, University of Texas Southwestern Medical Center, Virginia Commonwealth University, Lahey Hospital & Medical Center, Weill Cornell Medical Center and Northwell Health. Rush University Medical Center (approved 8 January 2020), Columbia University Medical Center (approved 28 January 2020), Northwestern University (approved 19 March 2020), Mount Carmel Health System (approved 5 May 2020) and Memorial Health University Medical Center (approved 4 April 2022) are regulated and were approved by their respective IRBs. Results from this trial will be presented at international conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER:NCT04095663.
Objective: Preoperative patient education improves surgical outcomes but high variability of existing patient education materials (PEMs) exists. This study establishes thoracic surgeon consensus on essential content included in PEMs to help patients to prepare for lung cancer surgery. Methods: Board-certified thoracic surgeons were recruited to participate through email invitations. Statements about the inclusion of topics in preoperative PEMs were crafted and divided into 6 categories. During 3 rounds of Delphi voting, surgeons gave anonymized feedback, and statements were iteratively revised. Results and comments of each round were shared with all surgeons for the next round of voting. Statements were considered to reach consensus if they achieved more than 80% agreement. Thematic qualitative analysis was performed on the comments provided. Results: A total of 41 board certified thoracic surgeons averaging 17.1 years in practice and 133 lung resections per year were recruited. Response rates were 93% (38 out of 41) for round 1, 88% (34 out of 38) for round 2, and 91% (31 out of 34) for round 3. The initial 25 statements were revised into 19 statements, of which 13 (68%) reached consensus. Statements with details about the operation itself had the highest consensus, whereas details about the day of surgery and recovery had the lowest consensus rates. Thematic analysis showed that statements were likely to be accepted if they were supported by evidence to improve surgical outcomes, set patient expectations, or alleviated anxiety. Statements were likely to be rejected if they were perceived to be irrelevant, could vary depending on practice, or could overwhelm patients. Conclusions: This study provides consensus-based guidelines on content that should be included in preoperative lung cancer surgery PEMs from thoracic surgeons’ perspective. Surgeon consensus gives valuable insight on topics that need expert opinion, whereas other topics require patient input. Patient preferences should be evaluated before finalizing guidelines.
The traditional management of acute coronary syndrome has relied on the identification of ST-segment elevation myocardial infarction (STEMI) as a proxy of acute coronary occlusion. This conflation of STEMI with acute coronary occlusion has historically overshadowed non-ST-segment elevation myocardial infarction (NSTEMI), despite evidence suggesting 25% to 34% of NSTEMI cases may also include acute coronary occlusion. Current limitations in the STEMI/NSTEMI binary framework underscore the need for a revised approach to chest pain and acute coronary syndrome management. The emerging paradigm distinguishing occlusion myocardial infarction from nonocclusion myocardial infarction (NOMI) seeks to enhance diagnostic accuracy and prognostic effect in acute coronary syndrome care. This approach not only emphasizes the urgency of reperfusion therapy for high-risk ECG patterns not covered by current STEMI criteria, but also emphasizes the broader transition from viewing acute coronary syndrome as a disease defined by the ECG to a disease defined by its underlying pathology, for which the ECG is an important but insufficient surrogate test. This report outlines the emerging occlusion myocardial infarction paradigm, detailing specific ECG patterns linked to acute coronary occlusion, and proposes a new framework that could enhance triage accuracy and treatment strategies for acute coronary syndrome. Although further validation is required, the occlusion myocardial infarction pathway holds promise for earlier acute coronary occlusion detection, timely cath lab activation, and improved myocardial salvage-offering potentially significant implications for both clinical practice and future research in acute coronary syndrome management.
Background The impact of tricuspid regurgitation (TR) on cardiac remodeling has not been thoroughly studied in a randomized controlled trial using advanced imaging. Objectives The goal of this analysis was to provide comparative longitudinal changes in right heart remodeling using cardiac magnetic resonance and time-resolved functional computed tomography (4D-CT) in patients with symptomatic severe TR randomized to TriClip vs medical therapy (control). Methods TRILUMINATE Pivotal (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal) is an international randomized controlled trial in symptomatic patients with severe TR. A prospective imaging substudy was performed on TRILUMINATE Pivotal subjects at 10 sites. Cardiac magnetic resonance and 4D-CT were performed following dedicated imaging protocols at baseline and at 30 days, and a final 4D-CT at 1 year (all assessed by an imaging core lab). Results Sixty-nine randomized subjects (31 TriClip, 38 control) were enrolled. TR volume significantly decreased with TriClip at 30 days (P < 0.0001; 70% reduction). A strong association (r = 0.90; P < 0.0001) was observed between changes in TR volume and right ventricular end-diastolic volume at 30 days. Significant reductions in right ventricular end-diastolic volume (12% reduction; P < 0.001) and tricuspid annular area (11% reduction; P < 0.0001) were seen at 30 days and sustained through 1 year with TriClip. No meaningful changes were observed in the control group. Conclusions Advanced imaging from the TRILUMINATE Pivotal imaging substudy demonstrated that TriClip effectively reduced TR. Significant cardiac remodeling was observed at 30 days and sustained at 1 year. With TriClip, the extent of cardiac remodeling was associated with the degree of TR reduction. (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal; NCT03904147)